Are you looking for “Sun Pharma share price target 2023, 2025, and 2027”? This article can help you find the answer in the most detailed way possible with our expert stock market analysts. Please read until the last word to get thorough knowledge.
Add a header to begin generating the table of contents
About Sun Pharma
Sun Pharma is India’s largest pharmaceutical company and the fourth largest globally. Dilip Sanghvi founded the company in 1983 in Gujarat. It has its headquarters in Mumbai. Sun Pharma has a presence in over 100 countries with its numerous products. In 2014 Sun Pharma acquired Ranbaxy, and with that, it became India’s largest Pharma company. The company has a rich production supply of generic and specialty medicines. Some of their products are generics, branded generics, specialty, difficult-to-make technology-intensive products, antiretrovirals, APIs, and intermediates. As per Wikipedia, the company has more than 36,000 employees.
Over 72% of Sun Pharma sales come from outside of India, interestingly 30% accounts from the USA.
Ratios of Sun Pharma
Ratios are the most important metrics to analyze a company in terms of its ability to make profits and sales growth.
Let’s look at Sun Pharma’s key ratios one by one in detail
P/E and P/B
The price-to-earnings ratio of Sun Pharma stood at 56.27 and the price-to-book ratio at 4.92 respectively.
ROE and ROCE – The ROE defines as Return on Equity which is at 6.93% and the ROCE ( Return on capital employed) is at 2.19%.
Sales growth
Stock history of Sun Pharma
| Year | Share Price |
| 2010 (Nov) | 176 |
| 2011 | 220 |
| 2012 | 292 |
| 2013 | 429 |
| 2014 | 628 |
| 2015 | 1,119 |
| 2016 | 815 |
| 2017 | 665 |
| 2018 | 512 |
| 2019 | 465 |
| 2020 | 457 |
| 2021 | 610 |
| 2022 | 924 |
| 2023 | 979 |
Sun pharma share price target 2023, 2025, and 2027
Sun Pharma has a strong market position in the generic dermatology segment. In 1994, the company has expanded to 24 other countries
Sun Pharma’s share target price for 2023
Sun Pharma is the leading pharmaceutical company in India, having more than an 8% market share. In 1988, Sun Pharma launched its first Monotrate and Angizem which are sold today.
As per our estimates, Sun Pharma’s share could rise to a level of 1,129 to 1,160
Sun Pharma’s share target price for 2025
The company heavily invests in research and development in the field of pharma products. They have a specialized set of labs that facilitates them to advance in their production.
The target price of Sun Pharma for the year 2027 will be 1,249 to 1,287
Sun Pharma’s share target price for 2027
The target price of Sun Pharma for the year 2027 will be 1,435 to 1,510
Sun Pharma’s share target price for 2030
The target price of Sun Pharma for the year 2027 will be 1,870 to 1,927
Conclusion
Sun Pharma is one of the top pharma companies in India, but their ROE and ROE are very low. As a result, the revenue correction may have contributed to the share price plummeting below 1000 levels. To calculate the share estimates, we purely use the current share price. Before considering this, please do your research.